Menu
Search
|

Menu

Close
X

Fennec Pharmaceuticals Inc FENC.OQ (NASDAQ Stock Exchange Capital Market)

9.45 USD
+0.06 (+0.64%)
As of 7:33 PM IST
chart
Previous Close 9.39
Open 9.36
Volume 1,563
3m Avg Volume 31,335
Today’s High 9.45
Today’s Low 9.35
52 Week High 14.85
52 Week Low 8.02
Shares Outstanding (mil) 15.86
Market Capitalization (mil) 234.13
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

No Data Available
Sell Hold Buy

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-0.085
FY17
-0.460
FY16
-0.215
FY15
-0.062
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
--
5.73
Price to Book (MRQ)
vs sector
18.65
5.45
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
0.00
16.72
LT Debt to Equity (MRQ)
vs sector
0.00
12.39
Return on Investment (TTM)
vs sector
-56.50
14.61
Return on Equity (TTM)
vs sector
-56.50
16.34

EXECUTIVE LEADERSHIP

Khalid Islam
Chairman of the Board, Since 2015
Salary: --
Bonus: --
Rostislav Raykov
Chief Executive Officer, Director, Since 2015
Salary: $178,462.00
Bonus: $40,000.00
Robert Andrade
Chief Financial Officer, Since 2015
Salary: $109,500.00
Bonus: --
Marco Brughera
Director, Since 2016
Salary: --
Bonus: --
Adrian Haigh
Independent Director, Since 2014
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

68 Tw Alexander Dr
PO Box 13628
DURHAM   NC   27709-3628

Phone: +1919.6364530

Fennec Pharmaceuticals Inc., formerly Adherex Technologies Inc., is a biopharmaceutical company focused on cancer therapeutics. The Company's lead product candidate in the clinical stage of development includes Sodium Thiosulfate (STS), which has completed patient enrollment of over two Phase III clinical trials for the prevention of cisplatin induced hearing loss, or ototoxicity in children. STS has been studied by cooperative groups in over two Phase III clinical studies of survival and reduction of ototoxicity, The Clinical Oncology Group Protocol ACCL0431 and SIOPEL 6. The Children's Oncology Group (COG) ACCL0431 protocol enrolled 20% childhood cancers typically treated with intensive cisplatin therapy for localized and disseminated disease, including hepatoblastoma, germ cell tumor, osteosarcoma, neuroblastoma and medulloblastoma. SIOPEL 6 enrolled only hepatoblastoma patients with localized tumors.

SPONSORED STORIES